# A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

> **NCT06469879** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 358 (estimated)

## Conditions studied

- Small Cell Lung Cancer Limited Stage

## Interventions

- **DRUG:** TQB2450+Anlotinib
- **DRUG:** TQB2450 placebo + Anlotinib placebo

## Key facts

- **NCT ID:** NCT06469879
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 358 (ESTIMATED)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06469879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06469879, "A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06469879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*